logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2017
ReGeneRx Biopharmaceuticals Inc
RGRX.OB
Topline data from U.S. Phase 3 trial of RGN-259
Neurotrophic keratopathy
Q3 2017
Versartis Inc.
Topline data from Phase 3 Study of VRS-317 (VELOCITY)
Growth Hormone Deficiency in children
2H 2017
Momenta Pharmaceuticals Inc
Topline data from phase 2 study of M402 in combination with nab-Paclitaxel and Gemcitabine
Metastatic Pancreatic Cancer
2H 2017
Otonomy Inc.
Results from phase 3 trial of OTO-104 (AVERTS-1)
Ménière’s disease
2H 2017
Otonomy Inc.
Results from phase 3 trial of OTO-104 (AVERTS-2)
Ménière’s disease
Q3 2017
ARCA biopharma, Inc.
Interim analysis of phase 2b /3 efficacy data of Gencaro (GENETIC-AF)
Atrial Fibrillation
Q3 2017
Amicus Therapeutics Inc.
Topline data from phase 3 study of SD-101 (ESSENCE)
Epidermolysis Bullosa
2H 2017
Tesaro Inc.
Data from phase 3 trial of Niraparib ( QUADRA)
Ovarian cancer
2H 2017
Acceleron Pharma, Inc
Topline results from phase 2 study of Dalantercept in combination with Axitinib
Renal cell carcinoma
2H 2017
Affimed N.V.
Primary endpoint data from phase 2a trial of AFM13
Relapsed/refractory Hodgkin lymphoma
2H 2017
GW Pharmaceuticals PLC
GWPH, GWP.L
Data from phase 2 study of CBDV
Partial-onset epilepsy
2H 2017
Nabriva Therapeutics
Top-line data from 2nd Phase 3 Trial of Lefamulin (LEAP 2)
Community-Acquired Bacterial Pneumonia
2H 2017
Prothena Corporation plc
Data from phase 1b proof-of-biology study of PRX003
Psoriasis
2H 2017
Neuralstem Inc.
Results from Phase 2 study of NSI-189
Treatment of major depressive disorder
2H 2017
CoLucid Pharmaceuticals, Inc.
Topline results from 2nd phase 3 trial of Lasmiditan (SPARTAN)
Migraine
Jul 2017
ImmunoCellular Therapeutics, Ltd.
Results from phase 1 open-label trial of ICT-121
Recurrent glioblastoma
01-Jul-2017 To 31-Aug-2017
Zynerba Pharmaceuticals, Inc.
Topline results from phase 2 study of ZYN002 cannabidiol (CBD) gel ( STAR 1)
Adult epilepsy patients with refractory focal seizures.
2H 2017
Catalyst Pharmaceutical Partners Inc.
Topline data from Phase 3 trials of Firdapse
Lambert–Eaton myasthenic syndrome (LEMS)
2H 2017
Catalyst Pharmaceutical Partners Inc.
Topline data from phase 3 trial of Firdapse
Congenital Myasthenic Syndromes
2H 2017
Cytokinetics Inc.
Results from phase 3 trial of Tirasemtiv (VITALITY-ALS)
Amyotrophic lateral sclerosis
2H 2017
Auris Medical Holding AG
Topline results from phase 3 trial of AM-111 (HEALOS)
Acute Inner Ear Hearing Loss
01-Jul-2017 To 31-Aug-2017
Zynerba Pharmaceuticals, Inc.
Topline results from phase 2 trial of ZYN002 CBD Gel (STOP)
Osteoarthritis
Q3 2017
Amarin Corp Plc
2nd pre-specified interim efficacy analysis of phase 3 trial of Vascepa (REDUCE-IT)
Cardiovascular outcomes study of Vascepa
Q3 2017
Corbus Pharmaceuticals Holdings, Inc.
Topline data from phase 2 study of Resunab
skin-predominant dermatomyositis
2H 2017
ReGeneRx Biopharmaceuticals Inc
RGRX.OB
Data from 2nd phase 3 trial of RGN-259
Dry Eye